Urolithin A analog inhibits castration-resistant prostate cancer by targeting the androgen receptor and its variant, androgen receptor-variant 7

We investigated the efficacy of a small molecule ASR-600, an analog of Urolithin A (Uro A), on blocking androgen receptor (AR) and its splice variant AR-variant 7 (AR-V7) signaling in castration-resistant prostate cancer (CRPC). ASR-600 effectively suppressed the growth of AR+ CRPC cells by inhibiti...

Полное описание

Библиографические подробности

Главные авторы:	Balaji Chandrasekaran, Ashish Tyagi, Uttara Saran, Venkatesh Kolluru, Becca V. Baby, Venkat R. Chirasani, Nikolay V. Dokholyan, Jyh M. Lin, Amandeep Singh, Arun K. Sharma, Murali K. Ankem, Chendil Damodaran
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Frontiers Media S.A. 2023-03-01
Серии:	Frontiers in Pharmacology
Предметы:	CRPC Androgen Receptor AR-Splice Variants N-terminal domain small molecule growth inhibition
Online-ссылка:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1137783/full
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!